Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations

References

• 1. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), S89–S119 (2012).
  Google Scholar
• 2. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23), e199–e267 (2014).
  MedlineGoogle Scholar
• 3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), S44–S88 (2012).
  Google Scholar
• 4. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414–1419 (2007).
  MedlineGoogle Scholar
• 5. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15), 1858–1866 (2006).
  Medline CASGoogle Scholar
• 6. Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries. JAMA Netw. Open 4(12), e2137288 (2021).
  MedlineGoogle Scholar
• 7. January CT, Wann LS, Calkins H et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 140(2), e125–e151 (2019).
  MedlineGoogle Scholar
• 8. Ortel TL, Neumann I, Ageno W et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 4(19), 4693–4738 (2020).
  Medline CASGoogle Scholar
• 9. Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, Mylonakis E. Medicare Part D prescribing for direct oral anticoagulants in the United States: cost, use and the “rubber effect.” PLOS ONE 13(6), e0198674 (2018).
  MedlineGoogle Scholar
• 10. Troy A, Anderson TS. National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019. JAMA Health Forum 2(7), e211693 (2021).
  MedlineGoogle Scholar
• 11. Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J. Clin. Pharm. Ther. 46(3), 560–570 (2021).
  Medline CASGoogle Scholar
• 12. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N. Engl. J. Med. 378(21), 2010–2021 (2018).
  Medline CASGoogle Scholar
• 13. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J. Biol. Chem. 257(19), 11210–11212 (1982).
  Medline CASGoogle Scholar
• 14. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(Suppl. 6), S160–S198 (2008).
  Google Scholar
• 15. Verhoef TI, Redekop WK, Daly AK, van Schie RMF, de Boer A, Maitland-van der Zee AH. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br. J. Clin. Pharmacol. 77(4), 626–641 (2014).
  Medline CASGoogle Scholar
• 16. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563–2570 (2007).
  Medline CASGoogle Scholar
• 17. Johnson JA, Caudle KE, Gong L et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther. 102(3), 397–404 (2017).
  Medline CASGoogle Scholar
• 18. Coumadin®, package insert. Bristol-Myers Squibb Company, Princeton, NJ, USA (2011).
  Google Scholar
• 19. Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997–2005 (2012).
  Medline CASGoogle Scholar
• 20. Zhang J, Wu T, Chen W, Fu J, Xia X, Chen L. Effect of gene-based warfarin dosing on anticoagulation control and clinical events in a real-world setting. Front. Pharmacol. 10, 1527 (2019).
  Medline CASGoogle Scholar
• 21. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294–2303 (2013).
  Medline CASGoogle Scholar
• 22. Sridharan K, Sivaramakrishnan G. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional. J. Clin. Pharm. Ther. 46(3), 640–648 (2021).
  Medline CASGoogle Scholar
• 23. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804–2812 (2010).
  Medline CASGoogle Scholar
• 24. Zhu Y, Xu C, Liu J. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. J. Clin. Pharm. Ther. 45(6), 1466–1473 (2020).
  Medline CASGoogle Scholar
• 25. Gage BF, Bass AR, Lin H et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA 318(12), 1115–1124 (2017).
  Medline CASGoogle Scholar
• 26. Huang SW, Chen HS, Wang XQ et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet. Genomics 19(3), 226–234 (2009).
  Medline CASGoogle Scholar
• 27. Carcas AJ, Borobia AM, Velasco M et al. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 13, 239 (2012).
  Medline CASGoogle Scholar
• 28. Lam YW. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol. 2013, 641089 (2013).
  MedlineGoogle Scholar
• 29. McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3(5), 751–759 (2007).
  Medline CASGoogle Scholar
• 30. Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype-guided dosing versus conventional dosing of warfarin: a meta-analysis of 15 randomized controlled trials. J. Clin. Pharm. Ther. 44(2), 197–208 (2019).
  Medline CASGoogle Scholar
• 31. Nutescu EA, Drozda K, Bress AP et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 33(11), 1156–1164 (2013).
  MedlineGoogle Scholar
• 32. Illinois Department of Public Health: Illinois hospital report card. Springfield, IL, USA. www.healthcarereportcard.illinois.gov/hospitals/view/101228
  Google Scholar
• 33. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326–331 (2008).
  Medline CASGoogle Scholar
• 34. Zolekar A, Kim K, Lee JC et al. Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Pharmacogenomics 23(2), 85–95 (2022).
  CASGoogle Scholar
• 35. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am. J. Epidemiol. 174(5), 613–620 (2011).
  MedlineGoogle Scholar
• 36. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am. J. Epidemiol. 158(3), 280–287 (2003).
  MedlineGoogle Scholar
• 37. Fahrni J, Husmann M, Gretener SB, Keo HH. Assessing the risk of recurrent venous thromboembolism – a practical approach. Vasc. Health Risk Manag. 11, 451–459 (2015).
  MedlineGoogle Scholar
• 38. Jorgensen AL, Prince C, Fitzgerald G et al. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Med. 17(1), 76 (2019).
  MedlineGoogle Scholar
• 39. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J. Thromb. Thrombolysis 35(3), 333–335 (2013).
  Medline CASGoogle Scholar
• 40. Shah RR. Genotype-guided warfarin therapy: still of only questionable value two decades on. J. Clin. Pharm. Ther. 45(3), 547–560 (2020).
  MedlineGoogle Scholar
• 41. Guimarães PO, Lopes RD, Alexander JH et al. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J. Thromb. Thrombolysis 48(1), 27–34 (2019).
  Medline CASGoogle Scholar
• 42. Aujesky D, Long JA, Fine MJ, Ibrahim SA. African American race was associated with an increased risk of complications following venous thromboembolism. J. Clin. Epidemiol. 60(4), 410–416 (2007).
  MedlineGoogle Scholar
• 43. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am. J. Med. 107(5), 414–424 (1999).
  Medline CASGoogle Scholar
• 44. Flaherty ML, Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 68(2), 116–121 (2007).
  Medline CASGoogle Scholar
• 45. Dobesh PP, Trujillo TC, Finks SW. Role of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism. Pharmacotherapy 33(6), 650–664 (2013).
  MedlineGoogle Scholar
• 46. Stafford L, van Tienen EC, Bereznicki LR, Peterson GM. The benefits of pharmacist-delivered warfarin education in the home. Int. J. Pharm. Pract. 20(6), 384–389 (2012).
  MedlineGoogle Scholar
• 47. Johnson SG. Improving cost–effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist. JMCP 15(Suppl. 6B), S19–S25 (2009).
  Google Scholar
• 48. Duvalyan A, Pandey A, Vaduganathan M et al. Trends in anticoagulation prescription spending among Medicare Part D and Medicaid beneficiaries between 2014 and 2019. J. Am. Heart Assoc. 10(24), e022644 (2021).
  MedlineGoogle Scholar
• 49. Manzoor BS, Walton SM, Sharp LK, Galanter WL, Lee TA, Nutescu EA. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. J. Thromb. Thrombolysis 44(4), 435–441 (2017).
  MedlineGoogle Scholar
• 50. Baker CL, Dhamane AD, Mardekian J et al. Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States. Adv. Ther. 36(1), 162–174 (2019).
  Medline CASGoogle Scholar
• 51. Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. Am. J. Manage. Care 24(Suppl. 8), SP309–SP314 (2018).
  MedlineGoogle Scholar
• 52. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule (2023). www.cms.gov/medicare/medicare-fee-for-service-payment/clinicallabfeesched
  Google Scholar
• 53. US Department of Veterans Affairs: Office of Procurement Acquisition and Logistics (Opal). Pharmaceutical prices. (2023). va.gov/OPAL/index.asp
  Google Scholar
• 54. Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br. J. Clin. Pharmacol. 79(2), 222–240 (2015).
  MedlineGoogle Scholar
• 55. Nutescu E, Duarte J, Cheng W et al. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. Circulation 130(Suppl. 2), A16119 (2014).
  Google Scholar
• 56. Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2), 315–352 (2016).
  MedlineGoogle Scholar